EMA Withdrawn: Pioglitazone Teva Pharma (pioglitazone hydrochloride) — Teva Pharma B.V.

View source ↗

Summary

The EMA has withdrawn the pioglitazone hydrochloride product Teva Pharma B.V. from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone Teva Pharma (pioglitazone hydrochloride) (pioglitazone hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Teva Pharma B.V.. Decision date: 21/06/2021